Hidden Bibliographic Details
| Other authors / contributors: | Buzdar, Aman U.
|
|---|
| ISBN: | 9780191575174
0191575178
9780199218141
0199218145
|
|---|
| Notes: | Includes bibliographical references and index.
Print version record.
|
|---|
| Summary: | Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromatase inhibitors are able toreduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen. New and emerging.
|
|---|
| Other form: | Print version: Endocrine therapies in breast cancer. Oxford ; New York : Oxford University Press, 2007 9780199218141
|
|---|
